IP Library Patent Application 18627105
Patent Application
App. No. 18/627,105

SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/627,105
Abstract

Disclosed herein are methods for the preparation of boronate derivatives in the synthesis of antimicrobial compounds and uses thereof. Disclosed herein includes method of making a compound of Formula (B) by reducing the ketone group of the keto-ester compound of Formula (A), and the reduction can be performed using a Ruthenium based catalyst system or using an alcohol dehydrogenase bioreduction system.

Claims (24)

1 . A method of making a compound of Formula (B), comprising the steps of:

reducing the ketone group of a compound of Formula (A):

to form a compound of Formula (B):

wherein:

X is Cl;

m is 2; and

the ketone group in the compound of Formula (A) is reduced using a Ruthenium based catalyst, wherein

the Ruthenium based catalyst has the structure of Formula (III):

X 1 is a halogen, benzene, cymene, or an acetyl (OAc) group; and

R 3 is a ligand selected from the group consisting of (S)-BINA, (R)—H 8 -BINAP, (R)-SegPhos, (R)-DM-SegPhos, (S)-SegPhos, (R)-xylyl-BINAP, (S)-tolyl-BINAP, (S)-PhanePhos, JosiPhos-2-1, (R)-SolPhos SL-A001-1, (S)-MeOBiPhep, (S)—P-Phos, and (S)-(+)-DTBM-SEGPHOS.

2 . The method of claim 1 , wherein X1 is a Cl or —OAc group.

3 . The method of claim 1 , wherein R3 is (R)-SegPhos.

4 . The method of claim 2 , wherein R3 is (R)-SegPhos.

5 . The method of claim 1 , wherein compound (B) is formed in an enantiomeric excess of greater than 80%.

6 . The method of claim 1 , wherein compound (B) is formed in an enantiomeric excess of greater than 90%.

7 . A method of making a compound of Formula (B), comprising the steps of:

reducing the ketone group of a compound of Formula (A):

to form a compound of Formula (B):

wherein:

X is Cl;

m is 2; and

the ketone group in the compound of Formula (A) is reduced using a Ruthenium based catalyst selected from the group consisting of [NH 2 Me 2 ][{RuCl((S)-SegPhos)} 2 (μ-Cl) 3 ] or [NH 2 Me 2 ][{RuCl((R)-DM-SegPhos)} 2 (μ-Cl) 3 ].

8 . The method of claim 7 , wherein compound (B) is formed in an enantiomeric excess of greater than 80%.

9 . The method of claim 7 , wherein compound (B) is formed in an enantiomeric excess of greater than 90%.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2025
From: VERZIJL, GERARDUS K.M.; HERMSEN, PETRUS J.
To: REMPEX PHARMACEUTICALS, INC.
Reel/Frame 071947/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2025
From: BOYER, SERGE HENRI; HECKER, SCOTT J.
To: REMPEX PHARMACEUTICALS, INC.
Reel/Frame 071947/0604 →
CHANGE OF NAME Recorded Aug 6, 2025
From: MELINTA THERAPEUTICS, INC.
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 071947/0767 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2025
From: REMPEX PHARMACEUTICALS, INC.
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 072370/0223 →
SECURITY INTEREST Recorded Aug 13, 2024
From: MELINTA SUBSIDIARY CORP.
To: FIRST-CITIZENS BANK & TRUST COMPANY
Reel/Frame 068260/0283 →